Congenital ornithine transcarbamylase deficiency (OTCD, OMIM 311250, Xp21.1) in humans results in hyperammonaemia with subsequent neurological symptoms including hypotonia, seizures and mental retardation. At the age of 3 years a hyperkinetic-hyperactive behaviour disorder of unknown origin was diagnosed in our female patient. The girl, ultimately diagnosed as having OTCD presented at the age of 6 years with an episode of feverassociated metabolic stroke including coma, epilepsy and further neurological symptoms due to hyperammonaemia. The pattern of plasma amino acids, the elevated level of orotic acid in urine and mutation analysis confirmed the diagnosis of OTCD. The possibility of early diagnosis and therapy of a disease which otherwise leads to severe neurological and psychiatric sequelae emphasizes the importance of precise evaluation of a possible organic cause for hyperkinetic-hyperactive behaviour disorders. This case of late-onset OTCD demonstrates that total recovery is possible even after a long comaepisode with slow reconvalescence. (J Pediatr Neurol 2004; 2(2): 97-100).
Introduction
Congenital ornithine transcarbamylase deficiency (OTCD, OMIM 311250, Xp21.1) is an Xlinked inherited disease and the most common inborn error of urea synthesis in humans. The incidence is estimated to be 1 per 14,000 (1) . Biochemical hallmarks of this disorder are hyperammonaemia, hyperglutaminaemia, elevated excretion of orotic acid, decreased arginine and citrulline.
The disease may occur in males from the neonatal period (40%) through adulthood, with late-onset disease (60%; 66% of whom are females) being associated with a milder phenotype (1). This is caused by different mutant alleles leading to differences in residual OTC activity (2) . In contrast, heterozygous females may be normal or may have episodes of hyperammonaemic encephalopathy and decline in cognitive function. Variable expression in females is most likely a function of the proportion of hepatocytes in which the active X-chromosome bears the mutant allele ("Lyon hypothesis"). OTCD patients may develop symptoms and metabolic derangement during metabolic stress such as infection precipitating protein catabolism. Prolonged hyperammonaemia and hyperammonaemic coma is associated with brain damage and impairment of intellectual function.
Case Report
Our patient is the 8-year-old daughter of non-consanguineous healthy parents of German extraction. She has one healthy brother, family history is unremarkable. At the age of 3 years a hyperkinetic-hyperactive behaviour disorder was diagnosed. She was put on methylphenidate therapy for one year without any benefit. At the age of 6 years she was referred to a hospital with increasing somnolence, hypotonia and dyskinesia during an episode of high fever. A diagnosis of OTCD was made based on laboratory findings including hyperammonaemia (306 µmol/L; normal < 50 µmol/ L), increased glutamine, low normal citrulline and decreased arginine concentrations in blood as well as elevated orotic acid and uracil in urine (Table  1) . Mutation analysis of the OTC gene revealed heterozygosity for the mutation 274C>T; R92X. Despite an early start of therapy with a low protein diet (~0.9 g/kg per day natural protein and essential amino acids), glucose infusion, supplemental Larginine, sodium benzoate and phenylbutyrate to remove excess nitrogen (for 4 weeks), our patient got comatose for one week. Over the following days and weeks the child slowly woke up showing a "flapping tremor" and seizures, which were treated with tiapride and oxcarbazepine. Determination of neurotransmitters in cerebral spinal fluid (CSF) was normal. 5-methyltetrahydrofolic acid concentration in CSF was decreased whereas folate levels in blood and erythrocytes were normal. Folate substitution was instituted.
Brain magnetic resonance imaging (MRI) and spectroscopy were performed (Figures 1-3 ). T2-weighted MRI showed an increased signal in the subcortical cerebral white matter (u-fibers) and a cerebellar atrophy. Diffusion-weighted images revealed lesions in the left insular and right occipital region. Complex peaks at 3.65-3.8 ppm were assigned to the glutamine/glutamate complex.
Three months after the admission the girl's mental and general condition were the same as before decompensation. One year after the metabolic stroke a good metabolic control and an improvement of psycho-mental development could be observed.
Discussion
This is the case of a now 8-year-old girl with OTCD presenting at the age of 6 years with an episode of fever-associated metabolic stroke including coma, hyperammonaemia and neurological impairment. At the age of 3 years a hyperkinetic-hyperactive behaviour disorder was diagnosed and she was put on methylphenidate therapy without any benefit. This behaviour disorder was probably a subtle manifestation of OTCD with subsequent episodes of hyperammonaemia.
Heterozygous females with OTCD show variable clinical features ranging from asymptomatic to severe illness depending on the proportion of hepatocytes in which the active X-chromosome bears the mutant allele ("Lyon hypothesis"). After the first MR spectroscopy a second one has been performed 9 months after the metabolic stroke. There was no change in the complex peak formation at 3.65-3.8 ppm, but there were no white matter lesions anymore. At that time concentrations of ammonia, glutamate and glutamine in blood and CSF were normal.
The reason for decreased folate levels in CSF is unclear. Possibly, toxic metabolites or drugs given to our patient may interfere with cerebral uptake or metabolism of folate.
Neuropathological evaluations from Butterworth 1,3,4) . These alterations suggest that the severe cognitive dysfunction in congenital OTCD may at least partly result from a muscariniccholinergic lesion. Another theory of pathogenesis is inhibition of the enzyme α-ketoglutaratedehydrogenase by excess of ammonia resulting in deficiency of pyruvate and acetyl coenzyme A. This can lead to impaired cerebral energy metabolism. Further explanations may relate to the toxic effects of metabolites and NMDA (glutamate) receptormediated excitotoxicity caused by energy depletion ("slow onset excitotoxicity") (3) (4) (5) .
Possible pathophysiologic mechanisms responsible for hyperammonaemic encephalopathy are the presence of oedema in the acute phase and damage to cortex and white matter in the chronic phase. Removal of excess ammonia in the brain proceeds by the formation of glutamine. There is evidence for osmotic effects of glutamine generated in astrocytes as a consequence of ammonia removal leading to brain swelling (6) . Another explanation may be alterations of serotonin synthesis and turnover in brain (3, 4) . Increased glutamine synthesis in brain may have deleterious effects, including a role in the stimulation of aromatic amino acid transport across the blood brain barrier. Although there is a strong correlation between the concentrations of ammonia and glutamine in blood, the elevation of glutamine concentration often occurs earlier and symptoms of encephalopathy appear already when ammonia concentrations are not excessively high (1) .
The increased signals predominantly present in subcortical regions in T2-weighted MR images in our patient are unspecific and can also be found in other metabolic disorders. Kurihara et al. (7) found small white matter lesions in children with OTCD and mild symptoms they also showed that MRI might be normal in the early stage of OTCD and deteriorate as clinical symptoms progress. The complex peaks in the MR spectroscopy found in our patient at 3.65-3.8 ppm have already been described in the literature and were assigned to the glutamine/glutamate complex (8) . Also Takanashi et al. (9) showed that the concentration of glutamine plus glutamate was increased in 4 of 6 patients with late onset OTCD which progressed in parallel with clinical stage. The lesions detected in the diffusionweighted MRI with reduction of the apparent diffusion coefficient were reported as a result of hypoperfusion (10) .
The aim of treatment is to control the hyperammonaemia, improve survival, prevent mental retardation and to ensure maintenance of cognitive function, normal psychomotor development and growth (11) . New therapeutic approaches aim at the correction of neurotransmitter (excitotoxicity) and cerebral energy deficits (Lcarnitin, NMDA receptor-antagonists) to improve cognitive function (3, 11, 12) .
In considering the development of gene therapy in OTCD Raper et al. (13, 14) focused on the use of liver directed gene therapy with an adenoviral vector. In a pilot study significant metabolic correction did not occur and one of 18 subjects experienced lethal complications (14) . Published data demonstrate that liver transplantation is a therapeutic option in OTCD. Whitington et al. (15) could demonstrate that liver transplantation resulted in control of hyperammonaemia in all patients (16 patients with urea cycle disorder, 10 with OTCD, two females). The neurological outcome Prolonged neonatal hyperammonaemic coma is associated with brain damage and impairment of intellectual function. Young primates developed a progressive reduction of consciousness that correlated in severity directly with the elevation of blood ammonia concentration (17, 18) . Our patient was comatose for about 7 days and she showed gradual improvements over the following three months. Despite this protracted course of coma our patient recovered completely from decompensation.
Conclusion
Early diagnosis and therapy of a disease which otherwise may lead to severe neurological symptoms and even death emphasizes the importance of a precise evaluation of a hyperkinetic-hyperactive behaviour disorders. After a "metabolic stroke" neurological impairment and sequelae may be completely reversible.
